Gene Logic Sees Growing Trend from Pharma Industry for Safety Testing

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 24, 2005--

    Over 350 Toxicity Screenings Completed on Clients' Proprietary Compounds, and Failed Drugs and Reference Compounds Using Gene Logic's Proprietary Toxicogenomics Predictive Models

    Gene Logic Inc. (NASDAQ:GLGC) announced today it has completed over 350 predictive toxicity assessments, using its proprietary toxicogenomics predictive models, on clients' live compounds, failed drugs and reference compounds profiled in various organ systems and primary rat hepatocytes. This genomics-based safety testing milestone underscores the drug development industry's growing need to identify possible risks prior to medicines entering human trials, and demonstrates the applied utility of toxicogenomics, a core technology for Gene Logic.
    Donna Mendrick, Ph.D., vice president, Toxicogenomics for Gene Logic, stated, "Pharmaceutical companies are recognizing the value of toxicogenomics as a means of prioritizing pipeline candidates and ensuring greater likelihood of success for drugs taken into the clinic. Recent events demonstrate the need for earlier analysis of safety. For this reason, toxicogenomics has evolved into a viable tool for prioritizing candidate drugs based on toxicity potential."
    As a basis for these toxicity screens, Gene Logic has developed and validated predictive toxicogenomic algorithms for more than 4 years as part of the development of its ToxExpress(R) System, a set of gene expression data obtained from animal studies on well- characterized reference compounds. The first application of this technology capability was released in 2003. Since that time, Gene Logic has continued to improve and develop additional predictive models based on animal model liver, kidney and heart tissues and primary hepatocytes.
    Dennis Rossi, Senior Vice President and General Manager, Genomics for Gene Logic, said, "This milestone signals a clear trend on the part of the industry toward characterizing the toxic potential of leads earlier, before large investments are made in downstream testing. We are encouraged that the toxicogenomics-based models we've developed over the past four years are increasingly providing our pharmaceutical customers important insights about their candidate compounds and helping them to improve their drug pipeline."

    Gene Logic Overview

    Gene Logic aspires to be the most valued drug development services provider for the pharmaceutical industry. Gene Logic applies its broad and unique mix of technologies, talent and methodologies to work on behalf of its partners to enable pharmaceutical and biotechnology companies to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.

--30--SF/ph*

CONTACT: Gene Logic Inc. Investors/Media: Robert G. Burrows, 301-987-1824 Email: rburrows@genelogic.com

KEYWORD: MARYLAND INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY PRODUCT SOURCE: Gene Logic Inc.

Copyright Business Wire 2005